Since sensitivity to LSD1 inhibition was associated with the presence or absence of expression of canonical neuroendocrine and mesenchymal markers in our previous analysis, we compared the GSK690 differentially expressed gene signature to an established gene coexpression network that delineates tumor heterogeneity observed in SCLC tumor samples as neuroendocrine (NE) and mesenchymal‐like (ML) [18, 19]. This evidence concerns the gene KDM1A and neoplasm.